Articles related to TARGETED THERAPIES

Discover how mechanoresilient cancer cells evade the body’s natural defenses and what this means for the future of targeted cancer therapies.

Understanding the ocular side effects of targeted cancer therapies is crucial. Early monitoring and interdisciplinary communication can significantly impact treatment outcomes.

Explore the intricacies of diagnosing and treating acral melanoma, a subtype that presents unique challenges but also offers new avenues for targeted therapies and immune modulation.

Explore the phase 1 study findings on Divarasib, a covalent KRAS G12C inhibitor, which has shown durable clinical responses with a favorable safety profile in patients with KRAS G12C-positive tumors.

The FDA’s recent approval of Akeega, a combination therapy for BRCA-mutated mCRPC, marks a significant advancement in targeted treatment. This approval, based on the MAGNITUDE study, offers a new therapeutic option for patients, supported by robust clinical data.

The targeted chemotherapy pill AOH1996, developed by the City of Hope, has shown promising results in preclinical research by targeting PCNA, a protein once thought to be too challenging for targeted therapy. Explore the potential of this novel approach as it advances to phase 1 clinical trials.